Dendritic cells generated in vivo by a chimeric hematopoietic growth factor, progenipoietin-4, demonstrate potent immunological function. (Articolo in rivista)

Type

• Articolo in rivista (Classe)
• Prodotto della ricerca (Classe)

Label

• Dendritic cells generated in vivo by a chimeric hematopoietic growth factor, progenipoietin-4, demonstrate potent immunological function. (Articolo in rivista) (literal)

Anno

• 2001-01-01T00:00:00+01:00 (literal)

Alternative label

• Ishioka GY, Fikes J, Qin M, Gianfrani C, Chesnut RW, Kahn LE, Streeter PR, Woulfe SL, Sette A. (2001)
  Dendritic cells generated in vivo by a chimeric hematopoietic growth factor, progenipoietin-4, demonstrate potent immunological function.
  in Vaccine
  (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#autori

• Ishioka GY, Fikes J, Qin M, Gianfrani C, Chesnut RW, Kahn LE, Streeter PR, Woulfe SL, Sette A. (literal)

Pagina inizio

• 3710 (literal)

Pagina fine

• 3719 (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#numeroVolume

• 19 (literal)

Rivista

• Vaccine (Rivista)

Note

• ISI Web of Science (WOS) (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#affiliazioni

• Epimmune Inc., 5820 Nancy Ridge Dr., San Diego, CA 92121, USA Pharmacia Corporation, 700 Chesterfield Village Parkway, St Louis, MO 63198, USA Istituto di Scienza dell'Alimentazione CNR (literal)

Titolo

• Dendritic cells generated in vivo by a chimeric hematopoietic growth factor, progenipoietin-4, demonstrate potent immunological function. (literal)

Abstract

• Recently, a dual receptor agonist for human Flt3 and G-CSF receptors, progenipoietin-4 (ProGP-4), was shown to be highly effective in expanding DC in vivo. In this study, we examined the immunological activity of ProGP-4-generated dendritic cell (DC) in an HLA-A2.1 transgenic mouse system. ProGP-4 DC were found to be approximately equivalent in presenting a cytotoxic T lymphocyte (CTL) peptide to a CTL line in vitro compared with bone marrow (BM)-derived DC and >20-fold more efficient than macrophages or B cells, and >100-fold better than BM-DC, macrophages, or B cells at presenting PADRE, a universal helper T cell epitope, to a T cell clone. The heightened epitope presentation by ProGP-4 DC was paralleled in vivo inasmuch as a >6-fold increase in CTL induction was observed compared with other APC populations following ex vivo loading with peptide. The in vitro and in vivo CTL responses stimulated by ProGP-4 DC could be further augmented by either culturing with tumor necrosis factor-alpha (TNF-alpha) or co-loading with PADRE. Collectively, our results indicate that peptide-loaded ProGP-4-generated DC demonstrate potent antigenicity and immunogenicity for CTL, making them an attractive component of epitope-based vaccines. (literal)

Prodotto di

• Institute of food sciences (ISA) (Istituto)

Autore CNR

• CARMELA GIANFRANI (Unità di personale interno)

Incoming links:

Prodotto

• Institute of food sciences (ISA) (Istituto)

Autore CNR di

• CARMELA GIANFRANI (Unità di personale interno)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#rivistaDi

• Vaccine (Rivista)